Antisoma changes Phase III leukaemia trial primary endpoint
This article was originally published in Scrip
Executive Summary
Antisoma has amended the primary endpoint of a Phase III ACCEDE trial testing its experimental chemotherapy drug AS1413 (amonafide L-malate) - one of its two lead products - in patients newly diagnosed with secondary acute myeloid leukaemia (secondary AML), following discussions with the FDA and trial investigators.